Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Sinclair
Harvard Medical School, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Life Biosciences (parent company) and Jupiter Orphan (wholly owned subsidiary operated by Life)
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research in this grant is to establish a specific molecular mechanism by which Sirt1 may be activated by resveratrol and synthetic resveratrol-like compounds, and to show that this putative allosteric activation of Sirt1 is responsible for the apparent beneficial effects of resveratrol. Jupiter Orphan Therapeutics is interested in using resveratrol as a therapeutic. Understanding and establishing a mechanism by which resveratrol and analogous compounds activate SIRT1 could increase their value as therapeutic agents. Jupiter Orphan Therapeutics was just subsumed by Life Biosciences and is now a wholly owned subsidiary owned and operated by Life. As such, Dr. Sinclair's financial interest in Life and its subsidiary, Jupiter Orphan Therapeutics, could directly and significantly affect the design, conduct or reporting of the research.
Elucidating mechanisms of SIRT1 activation
Project Narrative The sirtuins are some of the most mechanistically complicated enzymes known, playing important roles in the body's physiological responses to energy intake and exercise. But whether they can be directly activated by small molecules is hotly debated. This study will make use of a novel SIRT1 mutant we have discovered (hE230K/mE222K), which inhibits SIRT1 activation by small molecules. By assessing the effect of this mutation on SIRT1 structure and the effects of small molecule activators in primary cells and mice carrying this mutation, these studies will elucidate fundamental mechanisms of allosteric enzyme activation and resolve the debate as to whether sirtuins can be targeted directly for the treatment of type 2 diabetes and other metabolic diseases.
Filed on November 06, 2017.
Tell us what you know about David Sinclair's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Sinclair filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Sinclair | Harvard Medical School | Conflict of Interest | OvaScience | >$600,000 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Cohbar, Inc. | >$600,000 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences | $250,000 - $299,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Ovscience | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Ovscience | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | GlaxoSmithKline | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Senolytic Therapeutics | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | OvaScience | $10,000 - $19,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | GlaxoSmithKline | $5,000 - $9,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | OvaScience | $5,000 - $9,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences (parent company) and Jumpstart Fertility (wholly owned subsidiary operated by Life) | $0 - $4,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Jupiter Orphan Therapeutics | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Liberty Biosecurity (wholly owned and operated subsidiary of EdenRoc Sciences) and EdenRoc Sciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Liberty Biosecurity (wholly owned and operated subsidiary of EdenRoc Sciences) and EdenRoc Sciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | EdenRoc Science | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences (parent company) and Jumpstart Fertility (wholly owned subsidiary operated by Life) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Spotlight Biosciences Inc. | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Jumpstart Fertility (a subsidiary of Life Biosciences) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Senolytic Therapeutics | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Metrobiotech East, LLC | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | MetroBiotech Midatlantic, LLC | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | EdenRoc Sciences (parent company of Metro International Biotech and Liberty Biosecurity) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Iduna Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.